Addex Therapeutics Ltd (ADXN) FinancialsADXNAddex Therapeutics Ltd

Evaluating the bottom line, Addex Therapeutics Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -130.15%, provide a clear picture of how effectively ADXN converts its operational activities into shareholder value.

In the context of the broader market, ADXN competes directly with industry leaders such as ARTL and SPRC. With a market capitalization of $4.86M, it holds a leading position in the sector. When comparing efficiency, ADXN's gross margin of N/A stands against ARTL's N/A and SPRC's 73.71%. Such benchmarking helps identify whether Addex Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

Addex has shown a troubling financial performance with a net income loss of $2,184,326.19 in Q1 2026. The gross margin is inconsistent, with significant periods showing 100% but recent quarters indicating a lack of revenue generation. The current ratio has fallen to 0.97, suggesting liquidity issues.